Specification
Description
LGD-6972 is a glucagon receptor antagonist.
Synonyms
LGD-6972; LGD 6972; LGD6972; MB-11262; MB 11262; MB11262
IUPAC Name
(R)-2-(4-(2-(4'-(tert-butyl)-[1,1'-biphenyl]-4-yl)-3-oxo-3-((2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)propyl)benzamido)ethane-1-sulfonic acid
Canonical SMILES
O=C(NCCS(=O)(O)=O)C1=CC=C(C[C@H](C2=CC=C(C3=CC=C(C(C)(C)C)C=C3)C=C2)C(NC4=CC=C(C5=C(C)C=C(C)C=C5C)C=C4)=O)C=C1
InChI
InChI=1S/C43H46N2O5S/c1-28-25-29(2)40(30(3)26-28)35-17-21-38(22-18-35)45-42(47)39(27-31-7-9-36(10-8-31)41(46)44-23-24-51(48,49)50)34-13-11-32(12-14-34)33-15-19-37(20-16-33)43(4,5)6/h7-22,25-26,39H,23-24,27H2,1-6H3,(H,44,46)(H,45,47)(H,48,49,50)/t39-/m1/s1
InChI Key
HKJMCBYPVCGZFB-LDLOPFEMSA-N
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Alternative CAS
1207989-09-0 (free); 1207989-22-7 (sodium)
Biological Target
LGD-6972 is a selective and orally active glucagon receptor antagonist.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 73.48; H, 6.60; N, 3.99; O, 11.38; S, 4.56
HS Tariff Code
2934.99.9001
In Vivo Activity
Herein this study reports that treatment with the novel, potent GRA, LGD-6972, results in dose-related decreases from baseline in FPG in subjects with T2DM. Glucose reduction was observed in fasting and postprandial states. The effects on glycaemia in T2DM subjects were accompanied by dose-related increases from baseline in fasting glucagon, total GLP-1 and active GLP-1.
Reference: Diabetes Obes Metab. 2017 Jan;19(1):24-32. https://pubmed.ncbi.nlm.nih.gov/27501510/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).